Exult Healthcare is now Anchor. Same team, same clinics.

Call (972) 369-4220

Esketamine nasal spray

Spravato®

A different option for hard-to-treat depression.

What is Spravato®?

Spravato® (esketamine) is an FDA-approved treatment for treatment-resistant depression (TRD) in adults, used as a monotherapy or in combination with an oral antidepressant.

Treatment-Resistant Depression (TRD) is a subtype of MDD in which symptoms persist despite trying at least two standard treatments at the proper dose and duration.

2019
The FDA approved Spravato® nasal spray, used with an oral antidepressant, for adults with treatment-resistant depression.
2025
The FDA expanded the indication so adults with treatment-resistant depression can use it without an oral antidepressant.

How it works

Spravato® works differently, targeting glutamate in the brain to help restore neural connections involved in mood regulation.

Form

A nasal spray

Spravato® is a nasal spray.

Use

Alone or with an antidepressant

Adults with TRD can use it as a monotherapy or in combination with an oral antidepressant.

Access

A restricted program

Spravato® is available only through a restricted program called the Spravato® REMS.

Efficacy

In the ESCAPE-TRD trial (676 participants), 27.1% of people treated with esketamine nasal spray plus an SSRI/SNRI reached remission at eight weeks. With extended-release quetiapine plus an SSRI/SNRI, 17.6% reached remission.

27.1%
Remission at eight weeks · esketamine nasal spray plus an SSRI/SNRI
17.6%
Remission at eight weeks · extended-release quetiapine plus an SSRI/SNRI

Source 1: Reif A, et al. N Engl J Med. 2023;389:1298-1309.

Safety and side effects

Common side effects can include dissociation, dizziness, nausea, sedation, and increased blood pressure. Your clinician reviews the risks with you before treatment.

What to expect at the clinic

  1. 01

    Take your dose

    You take Spravato® yourself at the clinic, under the supervision of a healthcare provider.

  2. 02

    Stay for monitoring

    After each dose, the care team monitors you for at least two hours.

  3. 03

    Get a ride home

    Plan for someone else to drive you home. Do not drive or operate machinery until the next day, after a restful sleep.

Sources

  1. Reif A, et al. N Engl J Med. 2023;389:1298-1309. doi:10.1056/NEJMoa2304145
  2. U.S. FDA. Spravato® (esketamine) Prescribing Information. NDA 211243.

Further reading

This page is general information. It is not medical advice. Talk with a clinician about your own situation.

Get started

Finding the right treatment can take time. We’re here to help you understand your options.

Mon-Fri: 9:00 AM – 6:00 PM · Sherman and McKinney, Texas